Search
Huadong Medicine Announces FDA Approval for Phase I Clinical Trial of HDM2012 in the United States
5 day ago /
Read about 0 minute
Author：小编
Sino-US East China Pharmaceutical has announced that its wholly-owned subsidiary has received approval from the Food and Drug Administration (FDA) in the United States to initiate Phase I clinical trials for HDM2012, an injectable drug designed for the treatment of advanced solid tumors. This groundbreaking ADC (Antibody-Drug Conjugate) drug, independently developed by Sino-US East China Pharmaceutical, is the world's first to target MUC-17 and boasts global intellectual property rights.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
